Tirzepatide operates through the activation of both the GIP and GLP-1 receptors. GLP-1 receptor agonists stimulate insulin secretion and inhibit glucagon secretion in a glucose-dependent manner, leading to improved glycemic control. GIP receptor activation complements these effects, further enhancing insulin secretion in response to elevated blood glucose levels. By simultaneously targeting both receptors, Tirzepatide offers a robust and synergistic approach to diabetes management.